Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart
Authors
Park, Min
Nishimura, Takanori
Baeza-Garza, Carlos D.
Caldwell, Stuart T.
Pun, Pamela Boon Li
Prag, Hiran A.
Young, Tim
Sauchanka, Olga
Logan, Angela
Forkink, Marleen
Gruszczyk, Anja V.
Prime, Tracy A.
Arndt, Sabine
Naudi, Alba
Pamplona, Reinald
Coughlan, Melinda T.
Tate, Mitchel
Ritchie, Rebecca H.
Caicci, Federico
Kaludercic, Nina
Di Lisa, Fabio
Smith, Robin A. J.
Hartley, Richard C.
Murphy, Michael P.
Publication Date
2020-09-26Journal Title
Cardiovascular Drugs and Therapy
ISSN
0920-3206
Publisher
Springer US
Volume
34
Issue
6
Pages
823-834
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Park, M., Nishimura, T., Baeza-Garza, C. D., Caldwell, S. T., Pun, P. B. L., Prag, H. A., Young, T., et al. (2020). Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart. Cardiovascular Drugs and Therapy, 34 (6), 823-834. https://doi.org/10.1007/s10557-020-07086-7
Abstract
Abstract: Purpose: HFpEF (heart failure with preserved ejection fraction) is a major consequence of diabetic cardiomyopathy with no effective treatments. Here, we have characterized Akita mice as a preclinical model of HFpEF and used it to confirm the therapeutic efficacy of the mitochondria-targeted dicarbonyl scavenger, MitoGamide. Methods and Results: A longitudinal echocardiographic analysis confirmed that Akita mice develop diastolic dysfunction with reduced E peak velocity, E/A ratio and extended isovolumetric relaxation time (IVRT), while the systolic function remains comparable with wild-type mice. The myocardium of Akita mice had a decreased ATP/ADP ratio, elevated mitochondrial oxidative stress and increased organelle density, compared with that of wild-type mice. MitoGamide, a mitochondria-targeted 1,2-dicarbonyl scavenger, exhibited good stability in vivo, uptake into cells and mitochondria and reactivity with dicarbonyls. Treatment of Akita mice with MitoGamide for 12 weeks significantly improved the E/A ratio compared with the vehicle-treated group. Conclusion: Our work confirms that the Akita mouse model of diabetes replicates key clinical features of diabetic HFpEF, including cardiac and mitochondrial dysfunction. Furthermore, in this independent study, MitoGamide treatment improved diastolic function in Akita mice.
Keywords
Original Article, Diabetes, Heart failure with preserved ejection fraction (HFpEF), Akita mice, Advanced glycation endproducts (AGE), Mitochondria
Sponsorship
British Heart Foundation (PG/15/84/31670)
Consejo National de Ciencia y Technologia (n/a)
Medical Research Council (MC_U105663142)
Wellcome Trust (110159/Z/15/Z)
Biotechnology and Biological Sciences Research Council (BB/I012826/1)
Wellcome Trust (110158/Z/15/Z)
National Health and Medical Research Council (APP1059960)
Generalitat of Catalonia (SLT002/16/00250)
Department of Business and Knowledge (2017SGR696)
Identifiers
s10557-020-07086-7, 7086
External DOI: https://doi.org/10.1007/s10557-020-07086-7
This record's URL: https://www.repository.cam.ac.uk/handle/1810/313065
Rights
Attribution 4.0 International (CC BY 4.0)
Licence URL: https://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.